We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device.
- Authors
Riley, Andrew; Jones, Heidi; England, James; Kuvshinov, Dmitriy; Green, Victoria; Greenman, John
- Abstract
Although a large cohort of potential biomarkers for thyroid cancer aggressiveness have been tested in various formats in recent years, to the best of our knowledge, thyroglobulin and calcitonin remain the only two established biomarkers associated with thyroid cancer management. Our group has recently validated a novel means of maintaining live, human ex vivo thyroid tissue within a tissue-on-chip format. The present pilot study aimed to interrogate the tissue effluent, containing all the soluble markers released by the tissue samples maintained within the devices' tissue chamber, for the presence of markers potentially associated with thyroid cancer aggressiveness. Culture effluent from tissue samples harvested from 19 individual patients who had undergone thyroidectomy for the treatment of suspected thyroid cancer was assessed, first using a proteome profiler™ angiogenesis array kit. Patients were subcategorised as 'aggressive' if they possessed a minimum of N1b level metastases, whilst 'non-aggressive' samples were T3 or lower without evidence of multifocality; and contralateral healthy thyroid tissue was harvested for comparative studies. Levels of Serpin-F1, vascular endothelial growth factor, Thrombospondin-1 and chemokine (C-C motif) ligand were significantly altered and, thus, were further investigated using ELISA to allow for quantitative analysis. The concentration of serpin-F1 was significantly increased in the effluent of aggressive thyroid cancer tissue when compared with levels released by both non-aggressive and benign samples. The present study demonstrated the usability of microfluidic technology for the analysis of the ex vivo tissue secretome in order to identify novel biomarkers.
- Subjects
MICROFLUIDIC devices; VASCULAR endothelial growth factors; THYROIDECTOMY; MICROFLUIDIC analytical techniques; THYROID cancer; THYROID gland
- Publication
Oncology Letters, 2021, Vol 22, Issue 5, pN.PAG
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2021.13041